Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
- PMID: 37456430
- PMCID: PMC10348604
- DOI: 10.7759/cureus.40424
Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
Abstract
The use of erythropoiesis-stimulating agents (ESAs) reduces the need for recurrent blood transfusions in patients with advanced kidney disease. Rarely, allergic reactions to recombinant human erythropoietin can develop, complicating anemia management due to cross-reactivity between these agents. We report the use of an outpatient desensitization protocol, which was successfully completed in an adult patient who developed a maculopapular rash as a form of delayed-type hypersensitivity reaction (DTH) to epoetin-alfa (EPO) use, followed by successful re-introduction of EPO and continued tolerance.
Keywords: anemia of chronic diseases; chronic kidney disease (ckd); desensitization therapy; drug-induced hypersensitivity; synthetic epo.
Copyright © 2023, Panchal et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
-
A novel outpatient desensitization protocol for recombinant human erythropoietin allergy in a pediatric patient.Allergy Asthma Clin Immunol. 2018 Mar 12;14:8. doi: 10.1186/s13223-018-0233-1. eCollection 2018. Allergy Asthma Clin Immunol. 2018. PMID: 29545827 Free PMC article.
-
Epoetin-alfa induced pruritic maculopapular eruption: Case report and literature review.Asian Pac J Allergy Immunol. 2023 Sep;41(3):231-235. doi: 10.12932/AP-040719-0592. Asian Pac J Allergy Immunol. 2023. PMID: 32563229 Review.
-
Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.Clin Exp Nephrol. 2014 Oct;18(5):755-62. doi: 10.1007/s10157-013-0919-0. Epub 2013 Dec 7. Clin Exp Nephrol. 2014. PMID: 24317507
-
Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.Clin Ther. 2007 Sep;29(9):2010-21. doi: 10.1016/j.clinthera.2007.09.012. Clin Ther. 2007. PMID: 18035200
-
Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23. J Nephrol. 2018. PMID: 28646375
References
-
- Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Jones M, Ibels L, Schenkel B, Zagari M. Kidney Int. 2004;65:757–767. - PubMed
-
- Anemia in chronic kidney disease and its cardiovascular implications (Article in Spanish) Cases A, Coll E, Collado S. https://pubmed.ncbi.nlm.nih.gov/19460479/ Med Clin (Barc) 2009;132:38–42. - PubMed
-
- Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Fishbane S, Spinowitz B. Am J Kidney Dis. 2018;71:423–435. - PubMed
-
- Anaphylactic reaction to recombinant human erythropoietin. García JE, Senent C, Pascual C, et al. Nephron. 1993;65:636–637. - PubMed
-
- Anaphylactic shock at the end of hemodialysis. Aziz N, Luna C, Mirza F, Tobin M. Semin Dial. 2015;28:661–664. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials